Protara Therapeutics (TARA) launched a public offering of common shares.
Underwriters are expected to get a 30-day overallotment option for additional shares at the offering price, Protara said Monday in a statement.
Net proceeds are expected to fund the clinical development of TARA-002, among other things, the company said.
TARA-002 is an investigational cell therapy in development for the treatment of nonmuscle invasive bladder cancer and lymphatic malformations.
Protara's shares fell 8.7% in recent after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。